

SMART PARTNERSHIPS THAT ADVANCE CELL AND GENE THERAPY



Kinicipi is a new Welsh, Carson, Anderson & Stowe platform established to partner with companies that have the potential to transform the cell and gene therapy ecosystem to help deliver on the promise of these therapies to impact patients' lives.

A MARKET RIPE FOR RESOURCES

Bringing novel treatments to the patients who need them most — in an economically viable way — is too often crippled by persistent bottlenecks, constraints and inefficiencies in the development, manufacturing and delivery of those innovations.

At Kinicipi, our imperative is to make the promise of breakthrough cell and gene therapies a reality, so that future treatments reach patients as quickly and cost-efficiently as possible. There can't be a tradeoff between scientific advancements and patients' access to life-changing therapies; both must be addressed simultaneously.

WHERE URGENCY AND CAPABILITY MEET

Kinicipi is focused on investing in opportunities with the potential to leverage technology and capabilities that can help drive transformational change and ensure the promise of cell and gene therapies is delivered to patients in need. So we're ready and able to pursue partnerships in:

- Cell sources and other enabling quality-controlled starting and raw materials
- Enabling technology platforms (including cell-programming and gene-editing innovations)
- Key tools, services and enablers for process development and scale-up
- Innovations and solutions from source-to-patient delivery
- Other solutions designed to fulfill the promise of breakthrough treatments while concurrently reducing costs to ensure affordable access for patients

WHAT KINICITI BRINGS TO THE TABLE

In forming Kiniciti, Welsh, Carson, Anderson & Stowe (WCAS) hand-selected leading life sciences executives and committed a minimum of \$250M to support companies primed to transform healthcare through their cell and gene therapy offerings. While control-stake investments are part of our WCAS pedigree and our preference when appropriate, Kiniciti has a flexible remit to ensure that we invest in the right companies, with the right technology, at the right time. This may include growth equity and non-control stake structures that let you:

- Leverage decades of experience in growing and scaling companies across the healthcare sector both organically and through M&A activities
- Speed your commercial success through our vast sales, marketing and commercial excellence capabilities
- Benefit from our experience expanding businesses and building strong leadership and management teams to reach across North America, Latin America, Europe and Asia
- Collaborate with us to structure creative deals and partnering arrangements within the ecosystem
- Capitalize on our ability and agility to act quickly and bring vital resources to the table from our extensive network in the sector

KINICITI EXECUTIVE LEADS

GEOFFREY GLASS

Founding CEO

Geoff has spent more than 25 years helping lead services and therapeutic companies in the life sciences sector. He has served in executive leadership roles at EY, Valeant (now Bausch Health), Patheon (now Thermo Fisher Scientific), Sancilio Pharmaceuticals, and LongueVue Capital. In addition to leading Kiniciti, Geoff also currently serves as the Chairman of Avadel Pharmaceuticals (NASDAQ: AVDL).

JASON CONNER

Chief Strategy Officer

For over 20 years, Jason has helped high-growth life sciences companies in strategy, corporate development, and senior legal advisory roles. He recently served in the pharma services businesses of Thermo Fisher Scientific as Group Vice President, Strategy and General Counsel, after joining that business as part of the acquisition of Patheon Inc. Jason also spent a decade in private legal practice in the life sciences industry.

WCAS AT A GLANCE

WCAS is a leading private equity firm focused exclusively on healthcare and technology.

WCAS partners with organizations that add value to the ecosystem by reducing costs and improving the quality of care.

WCAS

40

Years of creating lasting partnerships with management

\$27B

Raised across 17 partnerships

35

Public companies in healthcare that can trace their roots to WCAS

10B

Equity capital invested in healthcare organizations

OUR INVESTMENT PARTNERS



LET'S START THE CONVERSATION

We'd like to learn more about your organization's focus, technology and objectives — and explore how a collaborative partnership could help you advance your work.

To get started, please get in touch with:

Geoffrey Glass gg@kiniciti.com

Jason Conner jc@kiniciti.com

(212) 650-4104 | kiniciti.com